先健科技控股子公司元心科技引入戰略投資
2020年11月25日,先健科技旗下專注於醫用生物可吸收金屬材料產品的研究、開發、製造及銷售的控股子公司——元心科技(深圳)有限公司(“元心科技”),順利引入了包括IDG資本、基石投資在內的多家戰略投資者,並已完成增資協議和股東協議的簽署。本次A輪新入投資者將按增資協議的約定合計向元心科技增資人民幣1.6億元,對應元心科技增資擴股後約13.19%的股權。交易完成後,先健科技仍對元心科技絕對控股。
元心科技的鐵基生物可吸收材料平台已歷經十餘年穩健發展,是全球生物可吸收支架領域的創新者和領跑者。本次獲得A輪戰略融資,是元心科技發展的重要里程碑,將為其後續發展帶來必要的資金支持,進一步有效地激勵鐵基項目團隊及吸收外部人才,加速鐵基項目的臨牀及上市審批進程。元心科技將高效利用資金,積極整合內外優勢資源,同時進一步豐富現有產品組合,推進業務的全面可持續發展,為全球患者帶來突破性的臨牀治療方案。同時,本次融資拉開了元心科技於資本市場獨立融資運作的序幕,行業領先的戰略投資者的加入將更好地助力元心科技的後續融資及資本化運作,進而提升元心科技及先健集團的整體價值。

元心科技是全球唯一從事鐵基可吸收支架研發的企業,具有先進的科研條件和高水平的研發團隊,致力於研發優秀的創新介入器械產品服務於廣大患者,解決全球未被滿足的臨牀需求。元心科技全球首創的鐵基生物可吸收材料平台,在醫療領域具有廣泛的應用空間和拓展潛力,目前已成功開發多款全降解鐵基生物可吸收支架產品,應用於冠心病、兒童肺血管狹窄和膝下動脈狹窄等多個主流業務領域。三款核心產品正處於臨牀和市場準入的不同階段,均已獲批進入國家創新醫療器械特別審查程序,目前各項工作推進順利,將為相關疾病的有效治療帶來重大突破。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.